Group 1 - The company Sichuan Enwei Pharmaceutical Co., Ltd. has recently obtained a renewed Drug Production License from the drug regulatory authority [1] - The renewed license is valid until July 17, 2030, and covers various forms of medication including ointments, granules, tablets, and traditional Chinese medicine [1] - The company has authorized Hunan Taiyang Pharmaceutical Co., Ltd. to produce its exclusive product, Jiangnao Pain Relief Liniment, with a change in the classification code [1][2] Group 2 - The production of Jiangnao Pain Relief Liniment is expected to enhance the company's product structure, meet market demand, and positively impact revenue and profit metrics [2] - The product is indicated for the auxiliary treatment of local pain and swelling caused by rheumatic arthritis, showcasing its therapeutic benefits [2]

Core Viewpoint - Enwei Pharmaceutical's wholly-owned subsidiary, Sichuan Enwei Pharmaceutical Co., Ltd., has recently obtained a renewed Drug Production License, which is expected to positively impact the company's market product structure and financial performance [1][2]. Group 1: License Information - Sichuan Enwei has received a renewed Drug Production License valid until July 17, 2030, allowing the production of various forms of medication including ointments, granules, tablets, and capsules [1]. - The license number is 川20160226, and the company is located at 458, Section 3, Shuanghua Road, Shuangliu District, Chengdu, Sichuan Province [1]. Group 2: Product and Market Impact - The license change includes the authorization for Hunan Taiyang Pharmaceutical Co., Ltd. to produce the exclusive Chinese medicine product, Jiangnao Pain Relief Liniment, which is used for treating local pain and swelling caused by rheumatic arthritis [2]. - The production and market launch of Jiangnao Pain Relief Liniment are expected to optimize the company's product structure, meet market demand, and enhance revenue and profit metrics, contributing positively to the company's long-term operations [2].